Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Biocept, Inc is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 88 staff and has a trailing 12-month revenue of around USD$5.7 million.
|Latest market close||USD$4.36|
|52-week range||USD$0.2112 - USD$4.89|
|50-day moving average||USD$6.788|
|200-day moving average||USD$5.4833|
|Wall St. target price||USD$20.3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.631|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-24)||1.40%|
|1 month (2020-09-01)||582.32%|
|3 months (2020-07-01)||529.51%|
|6 months (2020-04-01)||1,486.03%|
|1 year (2019-10-01)||436.55%|
|2 years (2018-10-01)||54.06%|
|3 years (2017-09-29)||254.47%|
|5 years (2015-10-01)||104.69%|
|Revenue TTM||USD$5.7 million|
|Gross profit TTM||USD$-5,448,954|
|Return on assets TTM||-56.44%|
|Return on equity TTM||-133.91%|
|Market capitalisation||USD$57.6 million|
TTM: trailing 12 months
There are currently 3.2 million Biocept shares held short by investors – that's known as Biocept's "short interest". This figure is 28.2% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Biocept shares can be evaluated.
Biocept's "short interest ratio" (SIR) is the quantity of Biocept shares currently shorted divided by the average quantity of Biocept shares traded daily (recently around 24.4 million). Biocept's SIR currently stands at 0.13. In other words for every 100,000 Biocept shares traded daily on the market, roughly 130 shares are currently held short.
However Biocept's short interest can also be evaluated against the total number of Biocept shares, or, against the total number of tradable Biocept shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biocept's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biocept shares in existence, roughly 20 shares are currently held short) or 0.0237% of the tradable shares (for every 100,000 tradable Biocept shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biocept.
Find out more about how you can short Biocept stock.
We're not expecting Biocept to pay a dividend over the next 12 months.
Biocept's shares were split on a 1:10 basis on 8 September 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Over the last 12 months, Biocept's shares have ranged in value from as little as $0.2112 up to $4.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.636. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.